News
New long-term extension data from the Phase IIb/III QUASAR trial demonstrate that Tremfya (guselkumab) maintains durable ...
In this video interview, C.K. Wang, MD, chief medical officer, COTA, touches on how he would like to see greater industry ...
The single-inhaler demonstrated a meaningful improvement in lung function in the Phase III KALOS and LOGOS studies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback